{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:17:28Z","timestamp":1794622648095,"version":"4.9.1"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T00:00:00Z","timestamp":1740009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-105595GB"],"award-info":[{"award-number":["PID2019-105595GB"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["PID2021-122726NB-I00"],"award-info":[{"award-number":["PID2021-122726NB-I00"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Ministry of Economy and Competitiveness | Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["FIS PI22\/00171"],"award-info":[{"award-number":["FIS PI22\/00171"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002809","name":"Generalitat de Catalunya","doi-asserted-by":"publisher","award":["2021SGR00042"],"award-info":[{"award-number":["2021SGR00042"]}],"id":[{"id":"10.13039\/501100002809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ayudas Fundaci\u00f3n BBVA a Proyectos de Investigaci\u00f3n Cient\u00edfica en Biomedicina 2021","id":[{"id":"https:\/\/ror.org\/01jzs3b90","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-56462-0","type":"journal-article","created":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:04:19Z","timestamp":1740027859000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Predicting immunotherapy response of advanced bladder cancer through a meta-analysis of six independent cohorts"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8355-6263","authenticated-orcid":false,"given":"Lilian Marie","family":"Boll","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-0269-8876","authenticated-orcid":false,"given":"Sergio","family":"V\u00e1zquez Montes de Oca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9319-6388","authenticated-orcid":false,"given":"Marta E.","family":"Camarena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2229-4508","authenticated-orcid":false,"given":"Robert","family":"Castelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2328-3421","authenticated-orcid":false,"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6809-132X","authenticated-orcid":false,"given":"J\u00falia","family":"Perera-Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7963-7375","authenticated-orcid":false,"given":"M. Mar","family":"Alb\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,20]]},"reference":[{"key":"56462_CR1","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015\u20131026 (2017).","journal-title":"N. Engl. J. Med."},{"key":"56462_CR2","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles, T. et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med. 383, 1218\u20131230 (2020).","journal-title":"N. Engl. J. Med."},{"key":"56462_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41588-018-0200-2","volume":"50","author":"D Miao","year":"2018","unstructured":"Miao, D. et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat. Genet. 50, 1271\u20131281 (2018).","journal-title":"Nat. Genet."},{"key":"56462_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41571-023-00826-2","volume":"21","author":"R Nadal","year":"2024","unstructured":"Nadal, R., Valderrama, B. P. & Bellmunt, J. Progress in systemic therapy for advanced-stage urothelial carcinoma. Nat. Rev. Clin. Oncol. 21, 8\u201327 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"56462_CR5","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002309","volume":"14","author":"A Snyder","year":"2017","unstructured":"Snyder, A. et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. PLoS Med. 14, e1002309 (2017).","journal-title":"PLoS Med."},{"key":"56462_CR6","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail, D. J. et al. High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann. Oncol. 32, 661\u2013672 (2021).","journal-title":"Ann. Oncol."},{"key":"56462_CR7","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1097\/CJI.0000000000000258","volume":"42","author":"EJ Davis","year":"2019","unstructured":"Davis, E. J. et al. Clinical Correlates of Response to Anti-PD-1\u2013based therapy in patients with metastatic melanoma. J. Immunother. 42, 221\u2013227 (2019).","journal-title":"J. Immunother."},{"key":"56462_CR8","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2217\/fon-2021-0273","volume":"17","author":"MD Galsky","year":"2021","unstructured":"Galsky, M. D. et al. Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905\/EV-303. Futur. Oncol. 17, 3137\u20133150 (2021).","journal-title":"Futur. Oncol."},{"key":"56462_CR9","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554, 544\u2013548 (2018).","journal-title":"Nature"},{"key":"56462_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson, A. G. et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171, 540\u2013556.e25 (2017).","journal-title":"Cell"},{"key":"56462_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun, A. et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur. Urol. 77, 420\u2013433 (2020).","journal-title":"Eur. Urol."},{"key":"56462_CR12","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315\u2013322 (2014).","DOI":"10.1038\/nature12965"},{"key":"56462_CR13","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"56462_CR14","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","volume":"75","author":"J Kim","year":"2019","unstructured":"Kim, J. et al. The Cancer Genome Atlas Expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. Eur. Urol. 75, 961\u2013964 (2019).","journal-title":"Eur. Urol."},{"key":"56462_CR15","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.cell.2021.01.002","volume":"184","author":"K Litchfield","year":"2021","unstructured":"Litchfield, K. et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition. Cell 184, 596\u2013614.e14 (2021).","journal-title":"Cell"},{"key":"56462_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33980-9","volume":"13","author":"JS Damrauer","year":"2022","unstructured":"Damrauer, J. S. et al. Collaborative study from the Bladder Cancer Advocacy Network for the genomic analysis of metastatic urothelial cancer. Nat. Commun. 13, 6658 (2022).","journal-title":"Nat. Commun."},{"key":"56462_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01024-y","volume":"14","author":"J Long","year":"2022","unstructured":"Long, J. et al. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape. Genome Med. 14, 20 (2022).","journal-title":"Genome Med."},{"key":"56462_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-42495-2","volume":"13","author":"LM Boll","year":"2023","unstructured":"Boll, L. M. et al. The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer. Sci. Rep. 13, 15287 (2023).","journal-title":"Sci. Rep."},{"key":"56462_CR19","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41416-021-01488-6","volume":"125","author":"TL Rose","year":"2021","unstructured":"Rose, T. L. et al. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. Br. J. Cancer 125, 1251\u20131260 (2021).","journal-title":"Br. J. Cancer"},{"key":"56462_CR20","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Mart\u00ednez-Jim\u00e9nez","year":"2020","unstructured":"Mart\u00ednez-Jim\u00e9nez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"56462_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s13402-022-00739-9","volume":"46","author":"Y Yang","year":"2023","unstructured":"Yang, Y. et al. Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity. Cell. Oncol. 46, 133\u2013143 (2023).","journal-title":"Cell. Oncol."},{"key":"56462_CR22","doi-asserted-by":"publisher","first-page":"v296","DOI":"10.1093\/annonc\/mdx371.003","volume":"28","author":"MD Galsky","year":"2017","unstructured":"Galsky, M. D. et al. Impact of zumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: Exploratory analysis of the phase ii checkmate 275 study. Ann. Oncol. 28, v296\u2013v297 (2017).","journal-title":"Ann. Oncol."},{"key":"56462_CR23","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"56462_CR24","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1126\/science.aad0095","volume":"350","author":"EM Van Allen","year":"2015","unstructured":"Van Allen, E. M. et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science 350, 207\u2013211 (2015).","journal-title":"Science"},{"key":"56462_CR25","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41416-019-0686-0","volume":"122","author":"AH Nassar","year":"2020","unstructured":"Nassar, A. H. et al. A model combining clinical and genomic factors to predict response to PD-1\/PD-L1 blockade in advanced urothelial carcinoma. Br. J. Cancer 122, 555\u2013563 (2020).","journal-title":"Br. J. Cancer"},{"key":"56462_CR26","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1158\/1078-0432.CCR-21-0575","volume":"27","author":"E Adib","year":"2021","unstructured":"Adib, E. et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin. Cancer Res. 27, 4025\u20134035 (2021).","journal-title":"Clin. Cancer Res."},{"key":"56462_CR27","doi-asserted-by":"crossref","unstructured":"Steen, C. B., Liu, C. L., Alizadeh, A. A. & Newman, A. M. Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. p. 135\u2013157 (Humana, New York, NY, 2020).","DOI":"10.1007\/978-1-0716-0301-7_7"},{"key":"56462_CR28","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1093\/intimm\/dxu095","volume":"27","author":"GK Philips","year":"2015","unstructured":"Philips, G. K. & Atkins, M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. Int. Immunol. 27, 39\u201346 (2015).","journal-title":"Int. Immunol."},{"key":"56462_CR29","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1200\/JCO.2017.74.7642","volume":"35","author":"R B\u00fcttner","year":"2017","unstructured":"B\u00fcttner, R. et al. Programmed death-ligand 1 immunohistochemistry testing: a review of analytical assays and clinical implementation in non\u2013small-cell lung cancer. J. Clin. Oncol. 35, 3867\u20133876 (2017).","journal-title":"J. Clin. Oncol."},{"key":"56462_CR30","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1038\/s41379-022-01119-2","volume":"35","author":"V Baxi","year":"2022","unstructured":"Baxi, V. et al. Association of artificial intelligence-powered and manual quantification of programmed death-ligand 1 (PD-L1) expression with outcomes in patients treated with nivolumab \u00b1 ipilimumab. Mod. Pathol. 35, 1529\u20131539 (2022).","journal-title":"Mod. Pathol."},{"key":"56462_CR31","doi-asserted-by":"publisher","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen, X. & Zhao, B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362, k3529 (2018).","journal-title":"BMJ"},{"key":"56462_CR32","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","volume":"24","author":"DF McDermott","year":"2018","unstructured":"McDermott, D. F. et al. Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. Nat. Med. 24, 749\u2013757 (2018).","journal-title":"Nat. Med."},{"key":"56462_CR33","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","volume":"387","author":"L Fehrenbacher","year":"2016","unstructured":"Fehrenbacher, L. et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet 387, 1837\u20131846 (2016).","journal-title":"Lancet"},{"key":"56462_CR34","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.immuni.2013.10.003","volume":"39","author":"G Bindea","year":"2013","unstructured":"Bindea, G. et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39, 782\u2013795 (2013).","journal-title":"Immunity"},{"key":"56462_CR35","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers, M. et al. IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930\u20132940 (2017).","journal-title":"J. Clin. Investig."},{"key":"56462_CR36","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu, R. et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 362, eaar3593 (2018).","journal-title":"Science"},{"key":"56462_CR37","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.medj.2023.07.006","volume":"4","author":"A Hernando-Calvo","year":"2023","unstructured":"Hernando-Calvo, A. et al. A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med 4, 710\u2013727.e5 (2023).","journal-title":"Med"},{"key":"56462_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.ccell.2023.12.005","volume":"42","author":"M Benguigui","year":"2024","unstructured":"Benguigui, M. et al. Interferon-stimulated neutrophils as a predictor of immunotherapy response. Cancer Cell 42, 253\u2013265.e12 (2024).","journal-title":"Cancer Cell"},{"key":"56462_CR39","doi-asserted-by":"publisher","first-page":"e000974","DOI":"10.1136\/jitc-2020-000974","volume":"8","author":"JC Thompson","year":"2020","unstructured":"Thompson, J. C. et al. Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma. J. Immunother. Cancer 8, e000974 (2020).","journal-title":"J. Immunother. Cancer"},{"key":"56462_CR40","doi-asserted-by":"publisher","unstructured":"Ouspenskaia, T. et al. Unannotated proteins expand the MHC-I-restricted immunopeptidome in cancer. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-021-01021-3 (2021).","DOI":"10.1038\/s41587-021-01021-3"},{"key":"56462_CR41","doi-asserted-by":"publisher","first-page":"108815","DOI":"10.1016\/j.celrep.2021.108815","volume":"34","author":"MV Ruiz Cuevas","year":"2021","unstructured":"Ruiz Cuevas, M. V. et al. Most non-canonical proteins uniquely populate the proteome or immunopeptidome. Cell Rep 34, 108815 (2021).","journal-title":"Cell Rep"},{"key":"56462_CR42","doi-asserted-by":"publisher","first-page":"eaau5516","DOI":"10.1126\/scitranslmed.aau5516","volume":"10","author":"CM Laumont","year":"2018","unstructured":"Laumont, C. M. et al. Noncoding regions are the main source of targetable tumor-specific antigens. Sci. Transl. Med. 10, eaau5516 (2018).","journal-title":"Sci. Transl. Med."},{"key":"56462_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05992-x","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang, L. et al. EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancer. Nat. Commun. 9, 3503 (2018).","journal-title":"Nat. Commun."},{"key":"56462_CR44","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1158\/2159-8290.CD-20-0522","volume":"10","author":"D Sha","year":"2020","unstructured":"Sha, D. et al. Tumor mutational burden as a predictive biomarker in solid tumors. Cancer Discov. 10, 1808\u20131825 (2020).","journal-title":"Cancer Discov."},{"key":"56462_CR45","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","volume":"27","author":"T Powles","year":"2021","unstructured":"Powles, T. et al. Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. Nat. Med. 27, 2200\u20132211 (2021).","journal-title":"Nat. Med."},{"key":"56462_CR46","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi, Y., Shitara, K. & Nishikawa, H. Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy. Nat. Rev. Clin. Oncol. 16, 356\u2013371 (2019).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"56462_CR47","doi-asserted-by":"publisher","first-page":"1550341","DOI":"10.1080\/2162402X.2018.1550341","volume":"8","author":"A Boichard","year":"2019","unstructured":"Boichard, A. et al. APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. Oncoimmunology 8, 1550341 (2019).","journal-title":"Oncoimmunology"},{"key":"56462_CR48","doi-asserted-by":"publisher","first-page":"4476","DOI":"10.1158\/0008-5472.CAN-20-0977","volume":"80","author":"J Bellmunt","year":"2020","unstructured":"Bellmunt, J. et al. Genomic predictors of good outcome, recurrence, or progression in high-grade T1 non\u2013muscle-invasive bladder cancer. Cancer Res. 80, 4476\u20134486 (2020).","journal-title":"Cancer Res."},{"key":"56462_CR49","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","volume":"18","author":"S Turajlic","year":"2017","unstructured":"Turajlic, S. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis. Lancet. Oncol. 18, 1009\u20131021 (2017).","journal-title":"Lancet. Oncol."},{"key":"56462_CR50","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/nature25015","volume":"553","author":"J Zhang","year":"2018","unstructured":"Zhang, J. et al. Cyclin D\u2013CDK4 kinase destabilizes PD-L1 via cullin 3\u2013SPOP to control cancer immune surveillance. Nature 553, 91\u201395 (2018).","journal-title":"Nature"},{"key":"56462_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36826-0","volume":"14","author":"W Barczak","year":"2023","unstructured":"Barczak, W. et al. Long non-coding RNA-derived peptides are immunogenic and drive a potent anti-tumour response. Nat. Commun. 14, 1078 (2023).","journal-title":"Nat. Commun."},{"key":"56462_CR52","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.isci.2018.10.021","volume":"9","author":"D Xiong","year":"2018","unstructured":"Xiong, D. et al. Immunogenomic landscape contributes to hyperprogressive disease after anti-PD-1 immunotherapy for cancer. iScience 9, 258\u2013277 (2018).","journal-title":"iScience"},{"key":"56462_CR53","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41587-021-01070-8","volume":"40","author":"D Chowell","year":"2022","unstructured":"Chowell, D. et al. Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. Nat. Biotechnol. 40, 499\u2013506 (2022).","journal-title":"Nat. Biotechnol."},{"key":"56462_CR54","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1038\/s41591-019-0654-5","volume":"25","author":"D Liu","year":"2019","unstructured":"Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916\u20131927 (2019).","journal-title":"Nat. Med."},{"key":"56462_CR55","doi-asserted-by":"publisher","DOI":"10.1002\/2056-4538.12363","volume":"10","author":"J Griffin","year":"2024","unstructured":"Griffin, J. et al. Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial. J. Pathol. Clin. Res. 10, e12363 (2024).","journal-title":"J. Pathol. Clin. Res."},{"key":"56462_CR56","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","volume":"66","author":"AV Balar","year":"2017","unstructured":"Balar, A. V. & Weber, J. S. PD-1 and PD-L1 antibodies in cancer: current status and future directions. Cancer Immunol. Immunother. 66, 551\u2013564 (2017).","journal-title":"Cancer Immunol. Immunother."},{"key":"56462_CR57","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda, A., Lin, D.-C., Assenov, Y., Plass, C. & Koeffler, H. P. Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res. 28, 1747\u20131756 (2018).","journal-title":"Genome Res."},{"key":"56462_CR58","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/ng.2760","volume":"45","author":"TI Zack","year":"2013","unstructured":"Zack, T. I. et al. Pan-cancer patterns of somatic copy number alteration. Nat. Genet. 45, 1134\u20131140 (2013).","journal-title":"Nat. Genet."},{"key":"56462_CR59","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0893-4","volume":"17","author":"R Rosenthal","year":"2016","unstructured":"Rosenthal, R., McGranahan, N., Herrero, J., Taylor, B. S. & Swanton, C. deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution. Genome Biol. 17, 31 (2016).","journal-title":"Genome Biol."},{"key":"56462_CR60","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41587-020-0439-x","volume":"38","author":"PA Ewels","year":"2020","unstructured":"Ewels, P. A. et al. The nf-core framework for community-curated bioinformatics pipelines. Nat. Biotechnol. 38, 276\u2013278 (2020).","journal-title":"Nat. Biotechnol."},{"key":"56462_CR61","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1093\/bioinformatics\/btu548","volume":"30","author":"A Szolek","year":"2014","unstructured":"Szolek, A. et al. OptiType: precision HLA typing from next-generation sequencing data. Bioinformatics 30, 3310\u20133316 (2014).","journal-title":"Bioinformatics"},{"key":"56462_CR62","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","volume":"199","author":"V Jurtz","year":"2017","unstructured":"Jurtz, V. et al. NetMHCpan-4.0: improved peptide-MHC Class I interaction predictions integrating eluted ligand and peptide binding affinity data. J. Immunol. 199, 3360\u20133368 (2017).","journal-title":"J. Immunol."},{"key":"56462_CR63","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15\u201321 (2013).","journal-title":"Bioinformatics"},{"key":"56462_CR64","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1093\/bioinformatics\/bts356","volume":"28","author":"L Wang","year":"2012","unstructured":"Wang, L., Wang, S. & Li, W. RSeQC: quality control of RNA-seq experiments. Bioinformatics 28, 2184\u20132185 (2012).","journal-title":"Bioinformatics"},{"key":"56462_CR65","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","volume":"30","author":"Y Liao","year":"2014","unstructured":"Liao, Y., Smyth, G. K. & Shi, W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics 30, 923\u2013930 (2014).","journal-title":"Bioinformatics"},{"key":"56462_CR66","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S H\u00e4nzelmann","year":"2013","unstructured":"H\u00e4nzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics 14, 7 (2013).","journal-title":"BMC Bioinformatics"},{"key":"56462_CR67","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/ijc.32982","volume":"147","author":"R Tokunaga","year":"2020","unstructured":"Tokunaga, R. et al. 12\u2010Chemokine signature, a predictor of tumor recurrence in colorectal cancer. Int. J. Cancer 147, 532\u2013541 (2020).","journal-title":"Int. J. Cancer"},{"key":"56462_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-14968-9","volume":"11","author":"C Chong","year":"2020","unstructured":"Chong, C. et al. Integrated proteogenomic deep sequencing and analytics accurately identify non-canonical peptides in tumor immunopeptidomes. Nat. Commun. 11, 1293 (2020).","journal-title":"Nat. Commun."},{"key":"56462_CR69","first-page":"548","volume":"92","author":"B Efron","year":"1997","unstructured":"Efron, B. & Tibshirani, R. Improvements on cross-validation: the 632+ Bootstrap Method. J. Am. Stat. Assoc. 92, 548\u2013560 (1997).","journal-title":"J. Am. Stat. Assoc."},{"key":"56462_CR70","unstructured":"Boll, L. M., & V\u00e1zquez Montes de Oca, S. BLCA_ICI_Response_Predictor (Version 1.0.0). GitHub repository. https:\/\/github.com\/EvolutionaryGenomics-GRIB\/BLCA_ICI_Response_Predictor, 10.5281\/zenodo.14095067 (2024)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56462-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56462-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T05:04:29Z","timestamp":1740027869000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-56462-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,20]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["56462"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-56462-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.04.18.589711","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,20]]},"assertion":[{"value":"27 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Potential conflicts of interest: J.B. has served in consulting or advisory roles for Astellas Pharma, AstraZeneca\/MedImmune, Bristol Myers Squibb, Genentech, Novartis, Pfizer, Pierre Fabre, and the healthcare business of Merck KGaA, Darmstadt, Germany; has received travel and accommodation expenses from Ipsen, Merck & Co., Kenilworth, NJ, and Pfizer; reports patents, royalties, other intellectual property from UpToDate; reports stock and other ownership interests in Rainier Therapeutics; has received honoraria from UpToDate; and has received institutional research funding from Millennium, Pfizer, Sanofi, and the healthcare business of Merck KGaA, Darmstadt, Germany. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1213"}}